Szyman Catherine M.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 5, 2022
- Accession no.
- 0001225208-22-006584
- Filed
- May 5, 2022
- Trade date
- May 3-4, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $2.45M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Szyman Catherine M.CIK 0001438538 | Officer (CVP, Critical Care) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2022 | Common Stock | AGrant or awardAcquired | +3,775 | $0.00 | $0 | 31,343.66 | Direct | |
| May 4, 2022 | Common Stock | MOption exerciseAcquired | +23,400 | $21.76 | +$509,184 | 54,743.66 | Direct | |
| May 4, 2022 | Common Stock | FTax withholdingDisposed | −493 | $105.93 | −$52,223.49 | 54,250.66 | Direct | |
| May 4, 2022 | Common Stock | SSaleDisposed | −3,796 | $105.88F3 | −$401,920.48 | 50,454.66 | Direct | |
| May 4, 2022 | Common Stock | SSaleDisposed | −9,155 | $104.18F4 | −$953,767.9 | 41,299.66 | Direct | |
| May 4, 2022 | Common Stock | SSaleDisposed | −10,449 | $105.10F5 | −$1,098,189.9 | 30,850.66 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 3, 2022 | Common Stock | AGrant or awardAcquired | +30,600 | $0.00 | $0 | 30,600 | Direct | |
| May 3, 2022 | Common Stock | AGrant or awardAcquired | +4,725 | $0.00 | $0 | 4,725 | Direct | |
| May 4, 2022 | Common Stock | MOption exerciseDisposed | −23,400 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $105.77 to $105.92. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $103.77 to $104.76. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.